Okayama, Japan

Masaharu Takigawa



Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2000-2013

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Journey of Masaharu Takigawa

Introduction

Masaharu Takigawa is a prominent inventor based in Okayama, Japan, renowned for his groundbreaking contributions in the field of regenerative medicine. With a career marked by the development of innovative solutions, he has secured a total of five patents, reflecting his commitment to advancing medical technology and improving patient outcomes.

Latest Patents

Among his latest inventions is a composition for the regenerative treatment of cartilage disease. This sophisticated formulation includes a PDE4 inhibitor as its active ingredient, combined with a biocompatible and biodegradable polymer. When formulated for local administration to the affected cartilage regions—such as through microsphere preparation—this pharmaceutical composition demonstrates exceptional effectiveness in the regenerative treatment of cartilage disorders.

Career Highlights

Masaharu Takigawa's professional journey includes significant tenure at Mitsubishi Tanabe Pharma Corporation, where he contributed to various innovative projects. His work in the pharmaceutical sector showcases his dedication to finding solutions for challenging medical conditions, particularly in regenerative treatments.

Collaborations

Throughout his career, Takigawa has collaborated with notable professionals in the field, including Takuya Tamatani and Katsunari Tezuka. These partnerships have enabled him to leverage shared expertise and push the boundaries of regenerative medicine research, fostering innovative advancements in treatment options.

Conclusion

Masaharu Takigawa's contributions to the field of regenerative medicine, underscored by his five patents, position him as a leading inventor dedicated to enhancing healthcare solutions. His latest work with PDE4 inhibitors and biodegradable polymers marks a significant step forward in the treatment of cartilage diseases, improving the lives of patients and paving the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…